

SK chemicals
2025 3Q Earnings Release



We care for the future.
Healthcare, Earthcare

Disclaimer

The financial information in this document are consolidated earnings results based on K-IFRS. (Korea International Financial Reporting Standards)

The performance data for Q3 2025 included in this material has been prepared for the convenience of investors and has not yet been reviewed by an external auditor. Therefore, some of the content may change during the accounting review process.

Additionally, please note that the future outlook included in this material is based on the current business environment and the company's management strategy and may change due to future changes in the business environment and strategy adjustments.



1

Earnings Release

Company Highlight
Performance Summary

3Q25 Highlight



Performance

Revenue 610bn KRW
(+43.1% YoY, +2.2% QoQ)

Operating Profit 15bn KRW
(Turn to a Profit YoY, QoQ)



Green Chemicals Business

Enhancing Recycle value chain, with Strengthened Branding and Marketing



Pharma Business

Viartis sales showing continued growth



Vaccine (SK bioscience)

Sanofi Beyfortus (RSV) injection started
Continued growth of IDT

Performance Summary

Consolidated

Revenue 610bn KRW (+43.1% YoY, +2.2% QoQ)


Increase in sales of consolidated subsidiaries and expansion in size due to strong performance in the separate

Operating Profit 15bn KRW (Turn to a Profit YoY, QoQ)

Turned to Profit as losses from consolidated subsidiaries narrowed


Revenue

(Unit: billion KRW)



Operating Profit and Margin

(Unit: billion KRW)



Separate

Revenue 372bn KRW (+11.9% YoY, Δ3.3% QoQ)


Despite decline in copolyester business, Sales increased due to strong performance in pharma business

Operating Profit 30bn KRW (+1.3% YoY, +18.8% QoQ)

Earnings remained strong, supported by solid profitability in Copolyester and Pharma Business


Revenue

(Unit: billion KRW)



Operating Profit and Margin

(Unit: billion KRW)



2 Performance



Performance by Business Unit (1)

Green Chemicals – Copolyester & Monomer

3Q25 Performance

Revenue **209bn KRW** ($\Delta 9.1\%$ YoY, $\Delta 13.7\%$ QoQ)
 Contraction in global demand,
 Slower Copolyester sales led to lower revenue


Operating Profit **34bn KRW** ($+9.2\%$ YoY, $\Delta 14.0\%$ QoQ)
 Maintained solid profitability,
 supported by stable raw material costs
 and strengthened marketing in core markets

4Q25 Outlook

Diversifying Portfolio
 by expanding high value-added products
 and developing new applications

Revenue


(Unit: billion KRW)




* Including performance of America/Europe copolyester sales subsidiaries

Operating Profit and Margin

(Unit: billion KRW)



Sales Volume Proportion by Region



□ China □ EU/America □ Korea □ Japan etc

* Data above only refers to Copolyester sales

Applications



Performance by Business Unit (2)

Life Science - Pharma

3Q25 Performance

Revenue **138bn KRW** (+63.6% YoY, +8.2% QoQ)

Continuing strong sales
of key products and distribution

Operating Profit **10bn KRW** (+80.7% YoY, +15.5% QoQ)


Increase in profit margins
as sales grow

4Q25 Outlook

Securing profitability,
while exploring new growth opportunities


Revenue

(Unit: billion KRW)




Operating Profit and Margin

(Unit: billion KRW)



Revenue Proportion



Main Products



Joins

Natural product based
anti-arthritic treatment



Ginexin

blood circulation
disorder treatment &
Cognitive enhancer



Rivastigmine patch

Anti-dementia
treatment patch



Performance by Business Unit (3)

Life Science - SK bioscience

3Q25 Performance

Revenue **151bn KRW** (+144.6% YoY, Δ 6.9% QoQ)

**Growth of Zoster & Varicella Vaccines
and IDT Biologika Sales Led to Revenue Growth**


Operating Profit **Δ 19bn KRW** (Loss Continued YoY, QoQ)

Increased sales contributed to reduction in losses


4Q25 Outlook

**Growth in SKYVAX exports,
Expansion of Sanofi Vaccine
distribution**

Revenue



Operating Profit



Overview

SKYVAX

- SKYCellflu: Price decline due to shift from 4-valent to 3-valent, while export remains solid
- SKYVaricella: Steady '25-'27 PAHO supply
- SKYZoster: Expanded coverage through continued growth in local gov't procurement

Vaccine distribution

- Sanofi Beyfortus(RSV): Preventive antibody injection started for '25-'26 season

IDT Biologika

- Secured overachievement incentives from clients

2-dose Varicella Vaccine

- Filed IND for Phase 3 Clinical Trial of 2-dose Varicella Vaccine

Pan-sarbeco Vaccine

- Initiated development of a Universal Vaccine Targeting Sarbecovirus


Business Update



Copolyester Growth Strategy

Seek further growth through increased sales of heat resistant, recycled and value-added strategic products

Copolyester & Monomer¹⁾ Performance Trends



High-Value Portfolio Expansion

ECOZEN

Opportunity

- Targeting competitor's core market
- Proactively respond to product substitution opportunities

Strategy

- Increase quality and capacity with dedicated facility retrofits (Operation from June, 2025)

ECOTRIA [®]

Opportunity

- Building a circular economy within each country
- Increase Demand in Recycle Solution

Strategy

- Investment in additional CR facilities to meet mid-long term demand expansion (targeted to be operational in early '26)

SKY GREEN

Opportunity

- Increased regulations on environmental and health issues
- demand for substitution of other materials


Strategy

- Customer-centric marketing - Brand Owner Lock-in

1) Including performance of America/Europe copolyester sales subsidiaries

Recycle Growth Strategy

Establishing a leading position in the global recycling market by completing the end-to-end value chain



"Achieving global competitiveness through the internalization of core assets at every stage of the value chain and offering tailored, optimized solutions to customers."

Recycle Achievements

Expanding collaboration areas with key automotive partners; gradual progress becoming visible

Commercialization Cases



Tirecord for EV cars

2Q 2024



Supplied to the global No.1 tire cord company and applied to Hankook Tire's EV tires



Carmat for major car makers

3Q 2025



Collaborated with the world's leading car mat company and completed validation for replacing nylon.



Headliners for EV3 Studycar

3Q 2025



Introduced as a partner for sustainable material technology in the 2025 Hyundai Motor Company Sustainability Report


Completed quality validation of CR PET, meeting the advantages and required performance of conventional materials

Strengthening Branding & Marketing

ECO PLETE "Introduce new premium brand "

- Combining ECO (sustainability) and PLETE (complete), differentiate from **SKY PET CR** for general-purpose use
- Prioritized application in automotive, beginning with Durmont, and potential for brand expansion into high value-added segments in the future

Customer Co-marketing "Separate exhibition area for Durmont"



△ K Show 2025 SK chemicals booth



△ Exhibition of Durmont products

SK Multiutility – Combined Heat and Power Generation (CHP) Plant

Securing competitiveness in the utility business through subsidiary's new power facility expansion

Business Introduction

■ Business Overview

- Convert to LNG-LPG, establishing eco-friendly district energy system
- Stable industrial power and steam supply within the area

■ CAPEX : Approximately 673 Billion KRW ¹⁾

■ Expected Benefits

- Eco-friendly energy transition reflecting carbon-neutral policies.
- Generating stable revenue by directly supplying electricity and steam to customers


■ Facility Production Capacity

[Existing] ²⁾ Steam : 490t/h , Electricity : 27MW

[New] Steam : 240t/h , Electricity : 300MW



△ Rendering of the new LNG CHP plant



3 Appendix

Financial Statements

Key Financial Information

Governance and Shareholders

Shareholder Returns



Financial Statements (Consolidated)

Balance Sheet

(Unit: billion KRW)

Items	2024	3Q25
Current assets	2,385	2,460
- Current account	1,819	1,826
- Inventory	566	634
Non-current assets	2,983	3,284
- Investment in affiliated companies and joint ventures	10	10
- Tangible property	2,459	2,637
- Intangible property	163	209
- Other Non-current assets	351	427
Total assets	5,368	5,744
Current liabilities	974	1,143
Non-current liabilities	1360	1,458
Total liabilities	2,334	2,602
Equity attributable to the parent company	2,202	2,278
- Capital stock	99	99
- Consolidated capital surplus	1,240	1,240
- Consolidated other components of equity	△22	△18
- Accumulated other comprehensive income	22	41
- Consolidated earned surplus	862	916
Non-controlling interest	832	864
Total equity	3,034	3,142
Total liabilities and equity	5,368	5,744

Income Statement

(Unit: billion KRW)

Items	3Q24	4Q24	1Q25	2Q25	3Q25
Revenue	426	514	537	597	610
- Cost of Revenue	332	412	403	477	461
- Gross profit from Revenue	95	102	134	120	149
- Revenue and administrative expenses	107	131	109	121	134
Operating profits	-12	-29	24	△1	15
- Other non-operating income	1	33	3	10	15
- Other non-operating expense	4	13	2	4	7
- Financial income	23	35	25	21	26
- Financial expense	23	34	30	31	29
- Share of profits	△0.4	△0.1	1	1	0.4
Earnings before interest and taxes	△16	△9	20	△4	20
- Income tax expense	△5	△19	△2	△12	△28
Consolidated net income	△11	10	21	8	48
- Equity attributable to the parent company	△4	8	20	14	43
- Non-controlling interest	△7	2	1	△6	5

Financial Statements (Separate)

Balance Sheet

(Unit: billion KRW)

Items	2024	3Q25
Current assets	812	872
- Current account	559	542
- Inventory	253	330
Non-current assets	1,294	1,311
- Investment in affiliated companies and joint ventures	444	500
- Tangible property	708	652
- Intangible property	31	33
- Other Non-current assets	110	125
Total assets	2,106	2,182
Current liabilities	708	677
Non-current liabilities	236	279
Total liabilities	944	956
Capital	99	99
Capital surplus	158	158
Other components of equity	△13	△9
Earned surplus	917	978
Total equity	1,161	1,226
Total liabilities and equity	2,106	2,182

Income Statement

(Unit: billion KRW)

Items	3Q24	4Q24	1Q25	2Q25	3Q25
Revenue	332	347	347	384	374
- Cost of Revenue	251	254	255	297	270
- Gross profit from Revenue	81	92	92	87	102
- Revenue and administrative expenses	52	61	55	62	72
Operating profits	30	32	37	25	30
- Other non-operating income	0.4	2	2	8	14
- Other non-operating expense	3	10	1	4	7
- Financial income	8	22	13	12	5
- Financial expense	16	22	16	22	10
Earnings before interest and taxes	19	24	34	20	31
- Income tax expense	4	4	7	4	7
Net income	15	20	27	16	25


Key Financial Information (Separate)

(Unit: billion KRW)

Division	2023					2024					2025		
	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q	4Q	Total	1Q	2Q	3Q
Cash and Cash Equivalents	326	222	215	245	245	250	407	341	177	177	301	324	322
Net Debt	387	412	393	360	360	423	414	397	403	403	426	446	424
CAPEX	81	24	23	31	159	21	22	16	15	74	10	11	11
Debt Ratio	82.9%	71.5%	69.9%	74.0%	74.0%	76.4%	90.3%	81.3%	68.4%	68.4%	80.4%	80.6%	78.0%
Current Ratio	128.9%	133.6%	125.7%	103.1%	103.1%	91.5%	112.0%	114.7%	120.5%	120.5%	139.5%	123.6%	128.7%
EBITDA	39	34	38	31	141	33	46	44	48	171	53	41	46
EBITDA (%)	12.6%	10.4%	11.8%	9.4%	11.0%	10.0%	13.2%	13.3%	14.2%	12.6%	15.3%	10.7%	12.4%
ROE	1.5%	0.4%	1.2%	0.6%	3.7%	0.8%	2.2%	1.3%	1.7%	6.1%	2.2%	1.3%	2.0%


Governance and Shareholders

Governance



*As of end of Q3 2025, Common shares only

Shareholder Composition




Shareholders Category	No. Shares
SK discovery & Affiliated Persons	7,368,861
National Pension	1,484,965
Foreign Investors	1,779,316
Individuals and Institutions	6,589,302
Treasury Stock	29,909
Total no. of issued shares	17,253,783

*As of end of Q3 2025, Common shares only


Shareholder Returns

Dividend

Payout Ratio



DPS (Common Share)



1) The amount includes special dividends, with a dividend of 4,500 KRW per share based on the pre-bonus issue in 2021
2) Includes interim dividends 400KRW
3) Record Date of Shareholder Closure is 8th August, 2025

Others

Jun 2017 Retirement of Stock ¹⁾

Oct 2021 Announced dividend policy ²⁾

Nov 2021 50% capital increase without consideration

Mar 2022 Announced Buy-back of Stock (50 Bn KRW)

Oct 2022 Retirement of Stock (50 Bn KRW) ³⁾

1) Retired 1,939,120 common shares (7.9% of the total issued shares)
2) Total dividend amount determined at a payout ratio of approximately 30% (based on separate net income excluding non-recurring gains and losses)
3) Retired 389,489 common shares

4 Business Introduction




Green Chemicals
Life Science
Global Network


Business Introduction Green Chemicals - Copolyester

Business Introduction

- Functional PETG replaces PC, PMMA, PVC
- Production Process



- Key Products and Applicability



Cosmetics



HHG



HA



Interior
Sheets



Packaging etc.

Core Strategy

- Virgin : Stable profit through high-value goods/portfolio improvement
- Recycle : Establishing entry barriers through market preemption and property standardization

Core Tasks and Strategy

Preempting CR Copolyester Market

- Expanding Recycle sales by cooperating with Global B/O
- Early customer commitments through MOUs, etc.

High-Value Portfolio Expansion

- Targeting High-Value Markets Based on Quality Competency
 - Expanding sales in high-value end-markets (cosmetics/HHG/HA)
 - Leading standardization by securing cosmetics B/O
 - Expanding sales through new applications, replacing other materials
- Expanding Strategic Products/Markets Based on Optimized Facilities
 - Shortening the expansion period of heat-resistant copolyester through early establishment³⁾ of dedicated facilities
 - Accelerating M/S expansion through property enhancement and application expansion

Business Introduction Green Chemicals - Recycle

Business Introduction

Production Process

CR-PET

=

R-BHET


+

R-BHET

R-Monomer

Mechanical Recycling vs. Chemical Recycling Comparison

Choosing Chemical Recycling Method Enables Closed Loop and Sustainability



Core Strategy

- Securing competency as the 1st to commercialize CR-PET in 2023
- Leading the CR-PET market through quality and cost competency

Core Tasks and Strategy

Vertical Integration of Raw Material Supply: Feedstock Innovation

- Internalizing key recycled raw materials (R-BHET) SK Shantou
- Expanding W-PET value chain through extended partnerships

Stabilization of SK Shantou and Advancing of HTR Technology

- Price and quality competitiveness of recycled products and expanding R-BHET production capacity
- Purification process improvement → washing process Normalization → HTR Conversion

Securing Cost Competitiveness at the Level of MR-PET

- Reduction in production costs: Alleviating customer price resistance and promoting market development


Strategic Expansion of CR-PET Sales

- Securing opportunities in the high-value CR-PET market and mass market based on cost competitiveness

Business Introduction Green Chemicals - Circular

Business Introduction

- Providing a Closed Loop Solution for Recycling Waste PET Generated During Customers' Production Processes
- Circular Solution



Core Strategy

- Recycling market is expected to form across various industries due to recycling regulations



EEE
WEEE¹⁾

- Obligated to recover and recycle 55-80% of production volume
- Need to establish a closed loop for consumables generated during the process



Automotive
ELV²⁾

- Obligation to use easily disassembled designs and recyclable/reusable materials, with 25% of materials from end-of-life vehicles by 2030
- Need to establish a closed loop for waste obtained from end-of-life vehicles



Fashion
ESPR³⁾

- Obligation for manufacturers to comply with eco-design considering environmental impact and disclose fuel usage during the manufacturing process
- Need to establish a closed loop, prohibiting the disposal of unsold inventory by 2030

... and many other industry needs

1) Waste of Electrical & Electronic Equipment: EU directive on the manufacture/use/disposal of electrical/electronic equipment


2) End of Life Vehicles Regulation: EU regulation on the recycling/reuse of end-of-life vehicles

3) Eco-design for Sustainable Products Regulation: EU regulation for eco-design of sustainable products

Business Introduction **Green Chemicals – Other Business**

BIO Materials

- 100% Eco-Friendly⁴⁾ BIO Material high-Performance Bio-Polyol that Replaces Polyurethane Uses That Are Difficult to Recycle
- Targeting eco-friendly needs by increasing applicability and cost competitiveness



High elastic recovery,
wear resistance,
high flexibility

Lower CO₂ Emissions
Compared to
PTMEG⁵⁾

Commercialized in
February 2022 CAPA:
5,000 Tons/yr

Key Markets and Commercialization Examples



Spandex



Synthetic
Leather



Black Yak shoe insoles
(Elastomer/Foam)



SRIXON Golf ball
(Urethane Cover)

Functional Materials


- Polyester-based adhesives and coatings (BON) and TPEE(PEL)
- Eco-friendly needs in various areas: Increased demand for chemical resistance and conversion to recycled products

Product Introduction and Applicability

SKY BON

SKY PEL

- Polyester-based adhesives and coatings
- Can Coating, Pre-coated metal, Hotmelt, Industrial adhesives, etc.
- TPEE³⁾
- Cable Jacket, Industrial tubes, Duct Mesh Chair Monofilament, etc.



1) PDO : Propanediol 2) PO3G : Poly Oxytrimethylene Glycol 3) TPEE: thermoplastic polyester elastomer 4) Eco-friendly refers to products made from biomass
5) Using Bio-Derived Raw Materials that Reduce Greenhouse Gas Emissions by Approximately 40% Compared to Conventional Petrochemical-Based PTMEG

Business Introduction Life Science - Pharma

Business Introduction

- Competitive product portfolio in botanical and synthetic drug market
- Possesses top-level marketing and partnership capabilities domestically

▪ Main Products

Ginexin-F



ginkgo leaf blood circulation
and cognitive function
enhancer

Joins



Natural arthritis
treatment

Trast



Patch-type
arthritis treatment

Mvix S



World's first film-type
erectile dysfunction
treatment

Rivastigmine Patch



Patch-type
dementia
treatment

Core Strategy

Continuous business expansion through securing growth drivers
based on competency

Mid-term Key Tasks

Strengthening marketing
alliance competitiveness

Natural pharmaceutical
Product value-up

Expanding Global C(D)MO

Securing R&D growth
drivers

Implementation Strategy

Strengthening strategic
partnership and
operation optimization

Diversifying raw
material sourcing and
expanding sales

Exploring new Countries
for New CMO
opportunities


Expanding to new
pipelines and accelerating
open Innovation



Exploring
New Biz Model

Global Network

● HQ(1) ● Domestic Plants(3) ● Overseas Offices (2) ● Overseas Plants (3) ● Overseas Corporations(4)



SK Shantou



- Certification** 2019 r-BHET , CR-PET Plant takeover (Shuye)
Mar 2023 Acquisition of Tangible Assets (Shuye)
- Construction** r-BHET , CR-PET etc.
- Production Capacity** r-BHET : 70K tons / CR-PET 50K tons Annually

Ulsan Plant



- Certification** ISO 14001(Environment) / ISO 45001 (Safety and Health) / ISO 9001(Quality)
- Construction** Sept 1989 PTA / DMT Plant completion
Jan 2001 CHDM / PETG Plant completion
Feb 2022 PO3G Plant completion
- Products** Copolyester resin, DMT etc.
- Production Capacity** 450K tons Annually ^{1) 2)}

Cheongju Plant (S HOUSE)



- Certification** K GMP/ EU GMP(Solid tablets, patches)
- Construction** July 2009 Cheongju plant acquisition
July 2012 Production building completion
Mar 2014 Patch building reconstruction
- Products** Solid tablets and patches
- Production Capacity** 760 mil. solid tablets, 66 mil. patch pouches annually

Andong Plant (L HOUSE)



- Certification** MFDS & EU GMP Certification
- Construction** Dec 2012 Construction Completed
- Products** Flu vaccine, varicella/herpes zoster vaccine, COVID vaccine (CMO/CDMO)
- Production Capacity** Approximately 500 mil. doses annually based on finished products

1) Reflecting operation of new production facility*(#4) from 15th Jun 2021
2) PETG, DMT etc. total capacity